<DOC>
	<DOC>NCT02693171</DOC>
	<brief_summary>The purpose of this study is to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.</brief_summary>
	<brief_title>Post-Marketing Assessment of Immunogenicity and Safety of Unituxinâ„¢ in High-Risk Neuroblastoma Patients</brief_title>
	<detailed_description>This is a multi-center, non-randomized, open-label study in patients with high-risk neuroblastoma to assess the immunogenicity, safety and tolerability of Unituxin combination therapy. Patients enrolled in the study were prescribed Unituxin for the treatment of high-risk neuroblastoma.</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patient has been diagnosed with highrisk neuroblastoma. Patient has been prescribed Unituxin and plans to start Unituxin therapy within 30 days of study entry. Patient must start Unituxin therapy no later than 200 days after Autologous Stem Cell Transplantation (ASCT). Written informed consent / assent must be obtained in accordance with institutional and ICH guidelines. Patient has received prior antiGD2 antibody therapy. Patient has participated in an investigational clinical trial with tumor therapeutic intent within 30 days of informed consent. Patient underwent Autologous Stem Cell Transplantation (ASCT) more than 200 days prior to receiving Unituxin therapy.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>